Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

E-hospital: Fully coordinated cancer care and research in Europe

Prof Alexander Eggermont - Gustave Roussy, Villejuif, France
E-hospital: Fully coordinated cancer care and research in Europe ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )
2 Oct 2014

The evolving treatment landscape for HER2-positive metastatic breast cancer

Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium
The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )
18 Sep 2014

ecancermedicalscience editor's choice for July and August 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for July and August 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
19 Aug 2014

WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care

Dr Oliver Bogler - MD Anderson Cancer Center, Houston, USA
WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care ( Dr Oliver Bogler - MD Anderson Cancer Center, Houston, USA )
26 Jun 2014

Gdf -11 a new target to improve anaemia in thalassemia

Prof Olivier Hermine - Université Paris Descartes, Paris, France
Gdf -11 a new target to improve anaemia in thalassemia ( Prof Olivier Hermine - Université Paris Descartes, Paris, France )
20 Jun 2014

LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer

Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA
LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer ( Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA )
12 Jun 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA )
2 Jun 2014

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
2 Jun 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2014

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
1 Jun 2014

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
1 Jun 2014